McKesson Corp (NYSE: MCK) reported Q1 FY23 adjusted EPS of $5.83, +5% Y/Y, beating the consensus of $5.27. Revenues increased 7% Y/Y to $67.15 billion, surpassing the consensus of $65.14 billion. U.S. Pharmaceutical segment's revenues were $56.9 billion, +14%, driven by an increased volume of specialty products, including higher volumes from retail national account customers, and market growth, partially offset by branded to generic conversions. Prescription Technology Solutions segment revenues
Investors seeking shelter from the market selloff are looking for some of the best cash cow stocks. Such a move is not surprising given that robust cash flow becomes more even valuable during economic downturns. For instance, the Pacer US Cash Cows 100 ETF (BATS:COWZ) is currently down 6.6% year-to-date (YTD) compared with the 17% loss for the S&P 500 index. The fund has seen assets under management skyrocket from $1.3 billion at the start of 2022 to the current $5.9 billion. Amid the market vol
In this article, we will discuss 10 best healthcare stocks to buy According to Larry Robbins. If you want to skip reading about Larry Robbins’ investment philosophy and his hedge fund’s returns, you can go directly to 5 Best Healthcare Stocks to Buy According to Billionaire Larry Robbins. Larry Robbins is an American investor and […]